The safety of polymyxin antibiotics

Expert Opinion on Drug Safety

Volumn 14, Issue 11, 2015, Pages 1687-1701

  Kelesidis, Theodoros ^a   Falagas, Matthew E ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimicrobial resistance; colistin; nephrotoxicity; neurotoxicity; polymyxin B; polymyxins; safety; toxicity

Indexed keywords

COLISTIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; ANTIINFECTIVE AGENT; POLYMYXIN;

ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HEMADSORPTION; HEMOFILTRATION; HUMAN; INCIDENCE; INTENSIVE CARE; META ANALYSIS (TOPIC); MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMICALLY INDUCED; KIDNEY DISEASES; MULTIDRUG RESISTANCE; NEUROTOXICITY SYNDROMES; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KIDNEY DISEASES; NEUROTOXICITY SYNDROMES; POLYMYXINS;

EID: 84947492691     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1088520     Document Type: Review

References (100)

1. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med 1962;266:759-62
2. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68
3. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
4. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977;46:723-63
5. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gramnegative bacterial infections. Clin Infect Dis 2005;40:1333-41
6. Danner RL, Joiner KA, Rubin M, et al. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989;33:1428-34
7. Vaara M. Novel derivatives of polymyxins. J Antimicrob Chemother 2013;68:1213-19
8. Li J, Nation RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
9. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
10. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21
11. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83
12. Claus BO, Snauwaert S, Haerynck F, et al. Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients. Int J Clin Pharm 2015;37(4):555-8
13. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005;37:142-5
14. Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 2008;31:80-2
15. Vasen W, Desmery P, Ilutovich S, Di Martino A. Intrathecal use of colistin. J Clin Microbiol 2000;38:3523
16. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect 2005;50:348-52
17. Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by highperformance liquid chromatography. Antimicrob Agents Chemother 2003;47:1364-70
18. Promixin 1 MIU powder for nebuliser solution [package insert]. West Sussex, UK: Profile Pharma Limited; 2003;2003
19. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gramnegative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51
20. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
21. Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilatorassociated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012;54:670-80
22. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilatorassociated pneumonia. J Infect 2008;56:432-6
23. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. The combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013;141:1214-22
24. Gu WJ, Wang F, Tang L, et al. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis. Int J Antimicrob Agents 2014;44:477-85
25. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65:1019-27
26. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010;65:2231-7
27. Kwon KH, Oh JY, Yoon YS, et al. Colistin treatment in carbapenemresistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents 2015;45:605-9
28. Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012;56:2392-6
29. Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study. J Antimicrob Chemother 2015;70:1552-7
30. Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011;117:c284-8
31. Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014;43:349-52
32. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrugresistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9
33. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720-6
34. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013;57:524-31
35. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54:1117-24
36. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624-30
37. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8
38. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1
39. Kubin CJ, Ellman TM, Phadke V, et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80-7
40. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35:473-7
41. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013;33:812-16
42. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31:1257-64
43. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879-84
44. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5
45. Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009;65:431-4
46. Nord NM, Hoeprich PD. Polymyxin B and Colistin. A critical comparison. N Engl J Med 1964;270:1030-5
47. Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3
48. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014;58:2740-6
49. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62
50. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-9
51. Yousef JM, Chen G, Hill PA, et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;55:4044-9
52. Yousef JM, Chen G, Hill PA, et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012;67:452-9
53. Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 2013;57:6319-24
54. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286:C913-22
55. Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998;275:F204-15
56. Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents 2005;26:504-7
57. Mostardeiro MM, Pereira CA, Marra AR, et al. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 2013;57:1442-6
58. Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: A comparative cohort study. Clin Microbiol Infect 2010;16:1230-6
59. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistininduced nephrotoxicity. Int J Antimicrob Agents 2009;34:434-8
60. Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect Dis 2013;13:380
61. Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit Care 2013;17:R174
62. Lee YJ, Wi YM, Kwon YJ, et al. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015;43:1187-93
63. Omrani AS, Alfahad WA, Shoukri MM, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015;14:3
64. Ceylan B, Tanis M, Akkoyunlu ME, et al. Variables determining the development of colistin-associated renal impairment. Wien Klin Wochenschr 2015. [Epub ahead of print]
65. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: A matched case-control study. Clin Infect Dis 2010;51:1238-44
66. Fekety FR Jr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962;57:214-29
67. Lamb R. Colistin sulphate in the treatment of specific bacterial intestinal infections. Scott Med J 1968;13:9-12
68. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11
69. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39-47
70. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-46
71. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study. Intensive Care Med 2005;31:1058-65
72. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: A matched case-control study. Intensive Care Med 2007;33:1162-7
73. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6
74. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90
75. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents 2009;33:503e501-13
76. Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009;37:461-5
77. Cheng CY, Sheng WH, Wang JT, et al. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297-300
78. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistinassociated nephrotoxicity. J Infect 2011;62:187-90
79. Turkoglu M, Dizbay M, Ciftci A, et al. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents 2012;39:142-5
80. Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015;9:476-85
81. Polat M, Kara SS, Tapisiz A, et al. Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children. Paediatr Drugs 2015;17(4):323-30
82. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65:2645-9
83. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gramnegative bacteremia. Clin Infect Dis 2013;56:398-404
84. Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85
85. Temocin F, Erdinc S, Tulek N, et al. Colistin-Associated Nephrotoxicity and Risk Factors. Jpn J Infect Dis 2015;68(4):318-20
86. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistintigecycline compared with colistincarbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: A multicenter prospective observational study. Crit Care Med 2015;43:1194-204
87. Holloway KP, Rouphael NG, Wells JB, et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939-45
88. Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother 2009;43:1948-55
89. Esaian D, Dubrovskaya Y, Phillips M, Papadopoulos J. Effectiveness and tolerability of a polymyxin B dosing protocol. Ann Pharmacother 2012;46:455-6
90. Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015;70:1903-7
91. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973;56:31-5
92. Shrestha A, Soriano SM, Song M, Chihara S. Intravenous colistin-induced acute respiratory failure: A case report and a review of literature. Int J Crit Illn Inj Sci 2014;4:266-70
93. Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522-9
94. Hoeprich PD. The polymyxins. Med Clin North Am 1970;54:1257-65
95. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987-92
96. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary clinical study of the effect of ascorbic Acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 2015;59:3224-32
97. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015;35:28-33
98. Bode-Boger SM, Schopp B, Troger U, et al. Intravenous colistin in a patient with serious burns and borderline syndrome: The benefits of therapeutic drug monitoring. Int J Antimicrob Agents 2013;42:357-60
99. Brandenburg KS, Rubinstein I, Sadikot RT, Onyuksel H. Polymyxin B self-associated with phospholipid nanomicelles. Pharm Dev Technol 2012;17:654-60
100. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistinmeropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227-30